Gossamer Bio, Inc. (NASDAQ:GOSS) Shares Purchased by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. grew its stake in shares of Gossamer Bio, Inc. (NASDAQ:GOSS) by 1.1% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 1,241,979 shares of the company’s stock after acquiring an additional 13,902 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Gossamer Bio were worth $1,123,000 at the end of the most recent reporting period.

Separately, The Manufacturers Life Insurance Company boosted its stake in shares of Gossamer Bio by 24.2% during the third quarter. The Manufacturers Life Insurance Company now owns 385,133 shares of the company’s stock valued at $380,000 after acquiring an additional 74,920 shares during the last quarter. 81.23% of the stock is currently owned by institutional investors and hedge funds.

Gossamer Bio Stock Up 0.9 %

GOSS opened at $1.17 on Monday. Gossamer Bio, Inc. has a 12 month low of $0.50 and a 12 month high of $1.55. The business has a 50-day moving average of $1.19 and a two-hundred day moving average of $0.99. The company has a debt-to-equity ratio of 3.64, a current ratio of 6.74 and a quick ratio of 6.74. The stock has a market capitalization of $265.85 million, a price-to-earnings ratio of -3.66 and a beta of 1.86.

Gossamer Bio (NASDAQ:GOSS) last issued its quarterly earnings results on Tuesday, March 18th. The company reported ($0.15) EPS for the quarter, hitting the consensus estimate of ($0.15). The company had revenue of $9.38 million for the quarter, compared to analyst estimates of $7.02 million. On average, research analysts expect that Gossamer Bio, Inc. will post -0.28 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have issued reports on GOSS shares. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Gossamer Bio in a report on Tuesday, March 18th. Wedbush restated an “outperform” rating and set a $4.00 target price on shares of Gossamer Bio in a research report on Friday, March 14th.

Gossamer Bio Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.